Type A and B Monoamine Oxidase in Age-Related Neurodegenerative Disorders: Their Distinct Roles in Neuronal Death and Survival

Current Topics in Medicinal Chemistry

Volumn 12, Issue 20, 2012, Pages 2177-2188

  Naoi, Makoto ^a   Maruyama, Wakako ^b   Inaba Hasegawa, Keiko ^a  

^a AICHI GAKUIN UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Apoptosis; Bcl 2; Neurodegeneration; Neuroprotection; Neurotrophic factor; Oxidative stress; Transcription factor; Type A and B monoamine oxidase

Indexed keywords

BEFLOXATONE; BROMOCRIPTINE; CABERGOLINE; CATECHOLAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LEVODOPA; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; N (1 INDENYL) N METHYL N PROPARGYLAMINE; NEUROTOXIN; NEUROTROPHIC FACTOR; NEUROTROPHIN; OXYGEN RADICAL; PERGOLIDE; PROTEIN BCL 2; RASAGILINE; REACTIVE OXYGEN METABOLITE; SALSOLINOL; SELEGILINE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; VOLTAGE DEPENDENT ANION CHANNEL;

ALZHEIMER DISEASE; APOPTOSIS; ASTROCYTE; CELL DEATH; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; HUMAN; LEWY BODY; MEMORY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; SUBSTANTIA NIGRA; SURVIVAL; UPREGULATION; WESTERN BLOTTING; X RAY CRYSTALLOGRAPHY;

EID: 84874824340     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612805219950     Document Type: Review

References (131)

1. Shih, J.C.; Ridd, M.J. Monoamine oxidase: From genes to behavior. Ann. Rev. Neurosi., 1999; 22, 197-217.
2. Edmondson, D.E.; Mattevi, A.; Binda, C; Hubalek F. Structure and mechanism of monoamine oxidase. Curr. Med. Chem., 2004; 11, 1983-1993.
3. Edmondson, D.E.; Binda, C; Mattevi A. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch. Biochem. Biophys., 2007, 464, 269-276.
4. Youdim, M.B.H.; Bakhle, Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J. Pharmacol., 2006; 147, S287-S296.
5. Johnston, J.P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol., 1968; 17, 30-36.
6. Bach, A.W.J.; Lan, N.C.; Johnson, D.L.; Abell, C.W.; Bembenek, M.E.; Kwan, S.W.; Seeburg, P.H.; Shih, J.C. cDNA cloning of human monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. USA, 1988; 85, 4934-4938.
7. Heikkila, R.E.; Manzino, L.; Cabbat, F.S.; Duvoisin R.C. Protection against the dopaminergic neurotoxiciy of 1-methyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine inhibitors. Nature, 1984; 311, 467-469.
8. Meyer, J.H.; Ginovart, N.; Boovariwala, A., et al. Elevated mono-amine oxidase A levels in the brain. An explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry, 2006; 63, 1209-1216.
9. Brunner, H.G.; Nelen, M.; Breakefield, X.O.; Ropers, H.H.; Van Oost B.A. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science, 1993; 262, 578-580.
10. Crane, G.E. The psychiatric effects of iporoniazid. Am J. Psychiatry, 1956; 122, 494-501.
11. Robinson, D.S. Monoamine oxidase inhibitors: a new generation. Gen Psychopharmcol., 2002; 36, 124-138.
12. Youdim, M.B.H.; Edmondson, D.; Tipton, K.F. The therapeutic potential of monoamine oxidase inhibitors. Nature Rev. Neurosci., 2006; 7, 295-309.
13. Bortolato, M.; Chen, K.; Shih J.C. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv. Drug. Deliv. Rev., 2008; 60, 1527-1533.
14. Naoi, M.; Maruyama W. Monoamine oxidase inhibitors as neuro- protective agents in age-dependent neurodegenerative disorders. Curr. Pharmaceutical Design, 2010; 16, 2799-2817.
15. Riederer, P.; Laux, G. MAO-inhibitors in Parkinson's disease. Exper. Neurol., 2011; 20, 1-17.
16. Lotufo-Neto, F.; Trivedi, M.; Thase, M.E. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropharmacol., 1999: 20, 226-247.
17. Naoi, M.; Maruyama, W.; Akao, Y.; Yi, H.; Yamaoka, Y. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J. Neural. Transm., 2006; [Suppl] 71, 67-77.
18. Yi, H.; Akao, Y.; Maruyama, W.; Chen, K.; Shih, Naoi M. Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SHSY5Y cells. J. Neurochem., 2006; 96, 541-549.
19. Naoi, M.; Maruyama, W.; Inaba-Hasegawa, K.; Akao, Y. Type A monoamine oxidase regulates life and death of neurons in neurode-generation and neuroprotection. Int. Rev. Neurobiol., 2011; 100, 85-106.
20. Tatton, W.G.; Ju, W.Y.L.; Holland, D.; Tai, C; Kwan M. Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem., 1994; 63, 1572-5157
21. Akao, Y.; Maruyama, W.; Yi, H.; Shamoto-Nagai, M.; Youdim, M.B.; Naoi, M. An anti-Parkinson's disease drug, N-propargyl- 1(R)-aminoindan (rasagiline) enhances expression of antiapoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett., 2002; 326, 105-108.
22. Maruyama, W.; Nitta, A.; Shamoto-Nagai, M.; Hirata, Y.; Akao, Y.; Youdim, M.; Furukawa, S.; Nabeshima, T.; Naoi, M. N- Propargyl-1-(R)-aminoindan, rasagiline, increases glial cell line- derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kB transcription factor. Neurochem. Int., 2004; 44, 293-400.
23. Riederer, P.; Lachenmayer, L.; Laux, G. Clinical applications of MAO-inhibitors. Curr. Med. Chem., 2004; 11, 2033-2043.
24. Westlund, K.N.; Denney, R.M.; Rose, R.M.; Abell, C.W. Localization of distinct monoamine oxidase A and monoamine oxidase B cell population in human brainstem. Neurosci., 1988; 25, 439-456.
25. Abeliovich, A.; Beal, M.F. Parkinsonism genes: culprits and clues. J. Neurochem., 2006; 99, 1062-1072.
26. Zhou, G.; Miura, Y.; Shoji, H.; Yamada, S.; Matsuishi T. Platelet monoamine oxidase B and plasma p-phenylethanolamine in Parkinson's disease. J. Neurol. Neurosurg Psychiatry, 2001; 70, 229-231.
27. Kurth, J.H.; Kurth, M.C.; Poduslo, S.E.; Schwankhaus, J.D. Association of a monoamine oxidase B allele with Parkinson's disease. Ann. Neurol., 1993; 33, 368-372.
28. Mellick, G.D.; Buchanan, D.D.; McCann, S.J. et al., Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease. Mov. Disord., 1999; 14, 219-224.
29. Costa-Mallen, P.; Afsharinejad, Z.; Kelada, S.N. et al., DNA sequence analysis of monoamine oxidase B gene coding and promotor regions in Parkinson's disease cases and unrelated controls. Mov. Disord., 2003; 19, 76-83.
30. O'Carroll, A.M.; Tipton, K.F; Sullivan, J.P; Fowler, C.J.; Ross, S.B. Intra- and extrasynaptosomal deamination of dopamine and noradrenalin by the two forms human brain monoamine oxidase implications for the neurotoxicity of N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in man. Biogenic Amines, 1987; 4, 165-178.
31. Williams-Gray, C; Goris, A.; Foltynie, T.; Compston, A.; Sawcer, S.; Barker, R.A. No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinson's disease. J. Neurol., 2009; 256, 132-133.
32. Nakamura, S.; Kawamata, T.; Akiguchi, I.; Kameyama, M.; Nakamura, N.; Kimura, H. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta. Neuropathol. Berl., 1990; 80, 419-425.
33. Riederer, P.; Danielczyl, W.; Grünblatt, E. Monoamine oxidase-B inhibition in Alzheimer's disease. Neuro. Toxicol., 2004; 26, 271-277.
34. Kennedy, B.P.; Ziegler, M.G.; Alford, M.; Hansen, L.A.; Thal, L.J.; Masliah, E. Early and persistent alterations in the prefrontal cortex MAO A and B in Alzheimer's disease. J. Neural. Transm., 2003; 110, 789-801.
35. Sparks, D.L.; Woeltz, V.M.; Markesbery, W.R. Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease. Arch. Neurol., 1991; 48, 718-721.
36. Wu, Y.H.; Fischer, D.F.; Swaab, D.F. A promotor polymorphism in the monoamine oxidase gene is associated with the pineal MAOA activity in Alzheimer's disease patients. Brain Res., 2007; 1167, 13-19.
37. Takehashi, M.; Tanaka, S.; Masliah, E.; Ueda, K. Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant. Neurosci. Lett., 2002; 327, 79-82.
38. Reed, J.C. Apoptosis-basis therapies. Nat. Rev. Drug Discovery, 2002; 1, 111-121.
39. Vila, M.; Przedborski, S. Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci., 2005; 4, 1-11.
40. Naoi, M.; Maruyama, W.; Yi, H.; Inaba, K.; Akao, Y.; Shamoto Nagai, M. Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neural death and survival. J. Neural. Transm., 2009; 116, 1371-1381.
41. Galluzzi, L.; Vitale, I.; Abrams, J.M. et al., Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death. Cell Death Differ., 2012; 19, 107-120.
42. Mizuno, Y.; Mochizuki, H.; Sugita, Y.; Goto, K. Apoptosis in neurodegenerative disorders. Int. Med., 1998; 37, 192-193.
43. Dawson, T.M.; Dawson, V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science, 2003; 302, 819-822.
44. M.F. Mitochondria take center stages in aging and neurode- generation. Ann. Neurol., 2005; 58, 495-505.
45. Terzioglu, M.; Galter, D. Parkinson's disease: genetic versus toxin- induced rodent models. FEBS J., 2008; 275, 1384-1391.
46. Storch, A.; Kaftan, A.; Burkhardt, K.; Schwarz, J. 6- Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. J. Neural. Transm., 2000; 17, 281-293.
47. Rodriguez-Blanco, J.; Martin, V.; Herrera, F.; Garcia-Santos, G.; Attolin, I.; Rodriguez, C. Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6- hydroxydopamine. J. Neurochem., 2008; 107, 127-140.
48. Naoi, M.; Maruyama, W.; Akao, Y.; Yi, H. Mitochondrial determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines. J. Neural Transm., 2002; 109, 607-621.
49. Levy, O.A.; Malagelada, C.; Greene, L.A. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis, 2009; 14, 478-500.
50. Cohen, G.; Farooqui, R.; Kesler, N. Parkinson disease: A new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. USA, 1997; 94, 489-494.
51. Schapira, A.H.V.; Mann, V.M.; Coooper, J.M. et al. Mitochondrial function in Parkinson's disease. Ann. Neurol., 1992; 32, S116-S124.
52. Keeney, P.M.; Xie, J.; Capaldi, R.A.; Bennett, J. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and its functionally impaired and misassembled. J. Neuro- sci., 2006; 26, 5256-5264.
53. Damier, P.; Kastner, A.; Agid, Y.; Hirsch, E.C. Does monoamine oxidase B play a role in dopaminergic nerve cell death in Parkinson's disease? Neurology, 1996; 46, 1262-1269.
54. Mallajosyula, J.K.; Kaur, D.; Chnta, S.J.; Rajagopalan, S.; Rane, A.; Nicholls, D.G.; Di Monte, D.A.; Macarthur, H.; Andersen, J.K.; MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLos ONE, 2008; 3, e1616.
55. Kunduzova, P.; Bianchi, P.; Pizzinat, N.; Escourrou, G.; Seguelas M.H.; Parini, A.; Cambon, C. Regulation of JNK/ERK activation, cell apoptosis, and tissue regeneration by monoamine oxidases after renal ischemia-reperfusion. FASEB J., 2002; 16, 1129-1131.
56. Mao, W.; Iwai, C.; Keng, P.C.; Vulapalli, R.; Liang, C. Norepi- nephrine-induced oxidative stress causes PC-12 cell apoptosis by both endoplasmic reticulum stress and mitochondrial intrinsic pathway: inhibition of phosphatidylinositol 3-kinase survival pathway. Am. J. Physiol. Cell Physiol., 2006; 290, C1373-1384.
57. Pchejetski, D.; Kunduzova, O.; Dayon, A, et al. Oxidative stress- dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Cir. Res., 2007; 100, 41-49.
58. Wu, R.M.; Murphy, D.L.; Chiueh, C.C. Suppression of hydroxyl radical formation and protection of nigral neurons by l-deprenyl (selegiline). Ann. NY. Acad. Sci., 1996; 786, 379-390.
59. Thomas, C.E.; Huber, E.W.; Ohlweiler, D.F. Hydroxyl and peroxyl radical trapping by the monoamine oxidase-b inhibitors deprenyl and MDL 72,974A: Implications for protection of biological substrates. Free Rad. Biol. Med., 1997; 22, 733-737.
60. Maruyama, W.; Takahashi, T.; Youdim, M.; Naoi, M. The antiparkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SHSY5Y cells. J. Neural. Transm., 2002; 109, 467-481.
61. Carrillo, M.C.; Kanai, S.; Nokubo, M.; Ivy, G.O.; Sato, Y.; Kitani, K. Deprenyl increases activities of superoxide dismutase and catalase in substantia nigra but not in hippocampus: The sex and age-related differences in the optimal dose in the rat. Exper Neurol., 1992; 116, 286-294.
62. Andoh, T.; Chock, P.B.; Murphy, D.L.; Chiueh, C.C. Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)deprenyl. Mol Pharmacol., 2005; 68, 1408-1414.
63. Takahata, K.; Shimazu, S.; Katsuki, H.; Yoneda, F.; Akaike, A. Effects of selegiline on antioxidant systems in the nigro-striatum in rat. J. Neural Transm., 2006; 113, 151-158.
64. Naoi, M.; Maruyama, W.; Dostert, P.; Hashizume, Y.; Nakahara, D.; Takahashi, T.; Ohta, M. Dopamine-derived endogenous 1(R),2(N)-dimethyl -6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induces parkinsonism in rat: biochemical, pathological and behavioral studies. Brain Res., 1996; 709, 285-295.
65. Akao, Y.; Nakagawa, Y.; Maruyama, W.; Takahashi, T.; Naoi, M. Apoptosis induced by an endogenous neurotoxin, N- methyl(R)salsolinol, is mediated by activation of caspase 3. Neuro- sci. Lett., 1999; 267, 153-156.
66. Maruyama, W.; Boulton, A.A.; Davis, B.A.; Dostert, P.; Naoi, M. Enantio-specific induction of apoptosis by an endogenous neuro- toxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine. J. Neural Transm., 201; 108, 11-24.
67. Minami, M.; Maruyama, W.; Dostert, P.; Nagatsu, T.; Naoi, M. Inhibition of type A and B monoamine oxidase by 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines and their N-methylated derivatives. J. Neural. Transm., 1993; 92, 125-135.
68. Wang, J.; Edmondson, D.E. Topological probes of monoamine oxidases A and B in rat lover mitochondria: Inhibition by TEMPO- substituted pargyline analogues and inactivation by proteolysis. Biochem., 2011; 50, 2499-2505.
69. De Zutter, G.S.; Davis, R.J. Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc. Natl. Acad. Sci. USA, 2001; 98, 6168-6173.
70. Ou X-M.; Chen, K.; Shih, J.C. Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc. Natl. Acad. Sci. USA, 2006; 103, 10923-10928.
71. Fitzgerald, J.C.; Ufer, C.; De Girolamo, L.A.; Kuhn, H.; Billet, E.E. Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells. J Neurochem., 2007; 103, 2189-2199.
72. Fitzgerald, J.C.; Ufer, C.; Billett, E.E. A link between monoamine oxidase A and apoptosis in serum derived human SHSY5Yneuroblastoma cells. J. Neural Transm., 2007; 114, 807-810.
73. Ou X-M.; Lu, D.; Johnson, C.; Chen, K.; Youdim, M.B.H.; Rajkowska, G.; Shih, J.C. Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotoxicity Res., 2009; 16, 148-159.
74. Ou, X-M.; Stockmeier, C.A.; Meltzer, H.Y. et al. A novel role for GAPDH-MAO B cascade in ethanol cellular damage. Biol. Psychiatry, 2010; 67, 855-863.
75. Shih, J.C.; Wu, J.B.; Chen, K. Transcriptional regulation and multiple functions of MAO genes. J. Neural Transm., 2011; 118, 979-986.
76. Pizzinat, N.; Marchal-Victorion, S.; Maurel, A.; Ordener, C.; Bompart, G.; Prini, A. Substrate-dependent regulation of MAO-A in rat mesangial cells: involvement of dopamine D2-like receptors. Am. J. Physiol. Renal Physiol., 2003; 284, F167-F174.
77. Manoli, I.; Le, H.; Alesci, S.; McFann K.S.Y.A.; Kino, T.; Chrousos, G.P.; Blackman, M.R. Monoamine oxidase-A is a major target gene for glucocorticoids in human skeletal muscle cells. FASEB J., 2005; 19, 1359-1361.
78. Ou, X.M.; Chen, K.; Shih, J.C. Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J Biol Chem., 2006; 281, 21512-21525.
79. Wu, J.B.; Shih, J.C. Valproic acid induces monoamine oxidase A via Akt/Forkhead box O1 activation. Mol. Pharmacol., 2011; 80, 714-723.
80. Grunewald, M.; Johnson, S.; Lu, D. et al. Mechanistic role for a novel glucocorticoid0KLF11 (TIEG2) protein pathway in stress- induced monoamine oxidase A expression. J. Biol Chem., 2012; 287, 24195-24206.
81. Cao, S.; Fernandez-Zapico, M.E.; Jin D.; Puri, V.; Cook, T.A.; 2Lerman, L.O.; Zhu, X-Y.; Urrutia, R.; Shah, V. KLF11-mediated repression antagonizes Sp1/sterol-responsive element-binding protein-induced transcriptional activation of caveolin-1 in response to cholesterol signaling. J. Biol. Chem., 2005; 280, 1901-1910.
82. Wu, J.B.; Chen, K.; Li, Y.; Lau, Y.FC.; Shih, J.C. Regulation of monoamine oxidase A by the SRY gene on the Y chromosome. FASEB, J., 2009; 23, 4029-4038.
83. Ou, X.M.; Chen, K.; Shih, J.C. Dual functions of transcription factors, transforming growth factor-like -beta-inducible early gene (TIEG) 2 and Sp3, are mediated by CACCC element and Sp1 site of human monoamine oxidase (MAO) B gene. J. Biol. Chem., 2004; 279, 21021-21028.
84. Wu, J.B.; Chen, K.; Ou, X.M.; Shih, J.C. Retinoic acid activates monoamine oxidase B promoter in human neural cells. J Biol Chem., 2009; 284, 16723-16735.
85. Jiang, H.; Jiang, Q.; Liu, J.; Feng, J. Parkin suppresses the expression of monoamine oxidases. J. Biol. Chem., 2006; 281, 8591-8599.
86. Gundlah, C.; Lu, N.Z.; Bethea, C.L. Ovarian steroid regulation of monoamine oxidase-A and -B mRNAs in the macaque dorsal raphe and hypothalamic nuclei. Pychopharmacol. (Berl), 2002; 160, 271-282.
87. Zhang, Z.; Chen, K.; Shih, J.C.; Teng, C.T. Estrogen-related receptors-stimulated monoamine oxidase B promoter activity is down- regulated by estrogen receptors. Mol. Endocrinol., 2006; 20, 1547-1561.
88. Ren, Y.; Jiang, H.; Ma D.; Nakaso, K.; Feng, J. Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases. Human Mol. Gen., 2011; 20, 1974-1083.
89. Itier, J.M.; Ibanez, P.; Mena, M.A, et al. Parkin gene inactivation alters behavioral and dopamine neurotransmission in the mouse. Human Mol. Gen., 2003; 12, 2277-2291.
90. Casarejos, M.J.; Solano, R.M.; Menendez, J.; Rodriguez-Navarro J.A.; Correa, C.; Garcia, de Yebenes J.; Mena, M.A. Differential effects of L-DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal-enriched cultures from parkin knockout and wild-type mice. J Neurochem., 2005; 94, 1005-1014.
91. Siddiqui, A.; Henson, I.; Andersen, J.K. Mao-B elevation decreases parkin's ability to efficiently clear damaged mitochondria; protective effects of rapamycin. Free Radic Res., 2012; in press.
92. Ringman, J.M.; Diaz-Olavarrieta, C.; Rodriguerz, Y. et al. Female preclinical presenilin-1 mutation carriers unaware of their genetic status lave higher levels of depression than their non-mutation carrier kin. J. Neurol. Neurosurg Psychiat., 2004; 75, 500-502
93. Nishimura, A.L.; Guindalini, C.; Oliveira, J.R.; Nitrini, R.; Bahia V.S.; de Brito-Marques, P.R.; Otto, P.A.; Zatz, M. Monoamine oxidase a polymorphism in Brazilian patients: risk factor for late- onset Alzheimer's disease? J. Mol. Neurosci., 2005; 27, 213-217.
94. Pennington, P.R.; Wei, Z.; Rui, L.; Dig, J.A, Graham, B.; Kuski, K.; Gabriel, G.G.; Mousseau, D.D. Alzheimer disease-related presenilin-1 variants exert distinct effects on monoamine oxidase-A activity in vitro. J. Neural Transm., 2011; 118, 987-995.
95. Wei, Z.; Gabriel, G.G.; Rui, L. et al., Monoamine oxidase-A physically interacts with presnilin-1 (M146V) in the mouse cortex. J Alzheimer's Dis., 2012; 28, 403-422.
96. Egashira, T.; Sakai, K.; Sakurai, M.; Takayama, F. Calcium disodium edetate enhances type A monoamine oxidase activity in monkey brain. Biol Trace Elem Res., 2003; 94, 203-211.
97. Birkmayer, W.; Knoll, J.; Riederer, P.; Youdim, M.B.H.; Hars, V.; Marton, J. Increased life expectancy resulting from addition of L- deprenyl to madopar treatment in Parkinson's disease; a longterm study. J. Neural Transm., 1985; 64, 113-127.
98. Akao, Y.; Maruyama, W.; Shimizu, S.; Yi, H.; Shamoto-Nagai M, Youdim, M.B.; Tsujimoto, Y.; Naoi, M. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and its inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J, Neurochem., 2002; 82, 913-923.
99. Youdim, M.B.H.; Buccafusco, J.J. CNS targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases. J Neural Transm., 2005; 112, 519-537.
100. Inaba-Hasegawa, K.; Akao, Y.; Maruyama, W.; Naoi, M. Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. J. Neural Transm., 2012; 119, 405-414.
101. Maruyama, W.; Akao, Y.; Youdim M.B.; Davis, B.A.; Naoi, M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3- phosphate dehydrogenase induced by an endogenous neurotoxin, N-methyl(R)salsolinol. J. Neurochem., 2001; 78, 727-735.
102. Maruyama, W.; Naoi, M. Induction of glial cell-line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: A way to a disease-modifying therapy? J. Neural Transm., 2012; in press.
103. Nakaso, K.; Nakamura, C.; Sato, H.; Imamura, K.; Takeshima, T.; Nakashima, K. Novel cytoprotective mechanism of anti-parkin sonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem Biophys Res. Commun., 2006; 339, 915-922.
104. Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson D.E.; Mattevi, A. Binding of rasagiline-related inhibitors to human monoamine oxidases; a kinetic and crystallographic analysis. J Med Chem., 2004; 48, 8148-8154.
105. Yi, H.; Maruyama, W.; Akao, Y.; Takahashi, T.; Iwasa, K.; Youdim, M.B.; Naoi, M. N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N- methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J. Neural. Transm., 2006; 113, 21-32.
106. Conner JM, Franks KM, Titterness AK, Russell K, Christie BR, Sejnowski TJ, Tuszynski MH. NGF is essential for hippocampal plasticity and learning. J Neurosci 2009; 29, 10883-10889.
107. Chauhan NB, Siegel GJ, Lee JM. Depletion of glial cell line- derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J Chem Neuroanat 2001; 21, 277-288.
108. Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A. Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J. Med. Chem., 2004;47, 1360-1366.
109. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D.E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase (MAO A): Relation to the structures of rat MAO A and human MAO B. Proc. Natl. Acad. Sci. USA, 2005; 102, 12684-12689.
110. Son, S.; Ma, J.; Kondou, Y.; Yoshimura, M.; Yamashita, E.; Tsukihara, T. Structure of human monoamine oxidase A at 2.2-A resolution: The control of opening the entry for substrates/inhibitors. Proc Natl. Acad. Sci. USA, 2008; 105, 5739-5744.
111. Hualek, F.; Binda, C.; Khalil, A.; Mattevi, A.; Catagnoli, N.; Edmondson, D.E. Demonstration of isoleucine 199 as a structural determination for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J. Biol. Chem., 2005; 280, 15761-15766.
112. Raddatz, R.; Parini, A.; Lanier, S.M. Imidazoline/guanidinium binding domains on monoamine oxidases. J. Biol. Chem., 1995; 270, 27961-27968.
113. Holt, A.; Berry, M.D.; Boulton, A.A. On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. Neuro, Toxicol., 2004; 25, 251-266.
114. Hara, M.; Snyder, S.H. Nitric oxide-GAPDH-Siah: a novel cell death cascade. Cell Mol. Neurobiol., 2006; 26, 527-538.
115. 3H]quinopirole binding at striatal D2 dopamine receptor by a monoamine-A-like site: evidence from radioligand studies and D2-receptor- and MAO(A)-deficient mice. Life Sci., 2001; 70, 229-241.
116. Ohta, K.; Kuno, S.; Mizuta, I.; Fujinami, A.; Matsui, H.; Ohta, M. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes. Life Sci., 2003; 73, 517-626.
117. Jorda, E.G.; Jimenez, A.; Verdaguer, E.; Canudas, A.M.; Folch, J.; Sureda, F.; Camins, A.; Pallas, M. Evidence in favour of a role for peripheral-type benzodiazepine receptor ligands in amplification of neural apoptosis. Apoptosis, 2005; 10, 91-104.
118. Heikkila, R.; Kindt, M.V.; Sonsalla, P.K. Giovanni A, Youngster SK, McKeown KA, Singer TP. Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA, 1988; 85, 6172-6176.
119. Kindt, M.V.; Youngster, S.K.; Sonsalla, P.K.; Duvoisin, R.C.; Heikkila, R.E. Role of monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal neurotoxicity of the MPTP analogs, 2'Me-MPTP. Eur. J. Pharmacol., 1988; 146, 313-318.
120. May, T. 1-Methyl-4-phenylpyridinium (MPP+) binds with high affinity to a p-carboline binding site localized on monoamine oxidase type A in rat brain. Neurosci Lett., 1993; 162, 55-58.
121. Chimenti, F.; Cottiglia, F.; Bousignore, L. et al. Quercetin as the active principle of Hypericum hircinum exerts a selective inhibitory activity against MAO-A: Extraction, biological analysis, and computational study. J. Nat. Prod., 2006; 69, 945-949.
122. Yanez, M.; Fraiz, N.; Cano, E.; Orallo, F. Trans-e-vinierin, a polyphenol present in win, is an inhibitor of noradrenaline and 5- hydroxytryptamine uptake and of monoamine oxidase activity. Eur J. Pharmacol., 2006; 542, 54-60.
123. Yanez, M.; Fraiz, N.; Cano, E.; Orallo, F. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem Biophys Res. Commun., 2006; 344, 688-695.
124. Marambaud, P.; Zhao, H.; Davies, P. Resveratrol promotes clearance of Alzheimer's disease amyloid-p peptides. J. Biol. Chem., 2005; 280, 27377-27382.
125. Ahmad, M., Saleem, S., Ahmad, A.S. et al. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioral, neurochemical and immunohistochemical evidences. J. Neurochem., 2005; 93, 94-104.
126. Pardon, M.C.; Joubert, C; Perez-Diaz F.; Christen, Y.; Launay, J.M.; Ohen-Salmon, C. In vivo regulation of cerebral monoamine oxidase activity in senescent controls and chronically stress-mice by long-term treatment with Ginkgo biloba extract (EGb 761). Mech Ageing Dev., 2000; 113, 157-168.
127. Rajeswari, A.; Sabesan, M. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice. Inflammopharmacol., 2008; 16, 96-99.
128. Begum, A.N.; Jones, M.R.; Lim, G.P. et al. Curcumin structure- function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J. Pharmacol. Exp. Ther., 2008; 326, 196-208.
129. Hou, W.C.; Lin, R.D.; Chen, C.T.; Lee, M.H. Monoamine oxidase B (MAO-B) inhibition by active principles from Uncaria rhynchophylla. J. Ethnopharmacol., 2005; 100, 216-20.
130. Hou, Y.; Aboukhatwa, M.A.; Lei, D.L.; Manaye, K.; Khan, I.; Luo, Y. Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacol., 2009; 58, 911-920.
131. Hynson, R.M.G.; Kelly, S.M.; Price, N.C.; Ramsay, R.R. Conformational changes in monoamine oxidase A in response to ligand binding or reduction. Biochim. Biophys. Acta., 2004; 1672, 60-66.